ClinicalTrials.gg
CompletedNCT07858344Updated Oct 15, 2026

Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIb Clinical Trial of Spray YJ001 for the Treatment of Diabetic Peripheral Neuropathic Pain

A Phase 2 interventional study of YJ001 spray simulator and YJ001 Spray 240 mg/day in Diabetic Peripheral Neuropathic Pain (DPNP), sponsored by Zhejiang Yuejia Pharmaceuticals Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Zhejiang Yuejia Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jan 2024, registered Sep 2026).
Updated Oct 15, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Neuralgia with a site in China — 16 open to participants now, 16 under way, 1 of them phase 3. Neuralgia · China.

Enrollment
11th of 30
196 · median 158
Started
2024
with 7 others
Phase 2
9 of 40
4 open now
Registered
39th of 40
by date

Among the 40 studies in Neuralgia with a site in China, this one is the 11th largest by enrollment of the 30 interventional ones that give a count, is one of 8 that started in 2024, is one of 9 in phase 2, and was the 39th registered.

Neuralgia

1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.

Browse Neuralgia studies →

Open to participants now

16 of the 40 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Neuralgia with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if YJ001 Spray can treat diabetic patients with Diabetic Peripheral Neuropathic Pain(DPNP). The main questions it aims to answer are:

  • Is YJ001 spray effective for patients with diabetic peripheral neuropathic pain(DPNP)?
  • The optimal effective dose of YJ001 spray for patients with diabetic peripheral neuropathic pain(DPNP).
  • Is YJ001 spray safe for patients with diabetic peripheral neuropathic pain(DPNP)? Researchers will divide YJ001 spray into three different doses of YJ001 spray and compare it with a placebo (a substance that looks similar but does not contain medication) to observe whether YJ001 spray can effectively treat diabetic peripheral neuropathic pain and to determine the optimal effective dose.

Participants will:

  • Apply spray topically to both feet twice daily, with six sprays per foot at each administration.Attend scheduled study visits at baseline and weeks 1, 2, 4, 8, and 12, followed by a visit 1 week after Treatment termination.
  • Record their symptoms and the number of times they use the spray.
03

Conditions studied

  • Diabetic Peripheral Neuropathic Pain (DPNP)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, between 18 to 75 years of age at screening
  • The subject is diagnosed with Type 1 or Type 2 diabetes with a disease duration of at least 1 year
  • The subject is diagnosed with diabetic peripheral neuropathic pain (DPNP, acceptable diagnostic certificates from other tertiary or higher-level hospitals.). Pain duration ≥ 3 months
  • level (HbA1c) ≤ 9%
  • At the screening visits, the score on the 11-point Numerical Rating Scale (NRS) must be ≥4.0. During the 1-week run-in period, subjects must complete at least 15 NRS scores, including 5 scores taken at 6 hours post-dose, and the mean pain score should have been ≥4.0
  • Subjects are willing and able to participate in study visits, treatment plans, laboratory tests, and other study procedures
  • Consented to participate in this study and signed the written form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Subjects who are known or suspected to be allergic to or have had severe adverse reactions to the ingredients of YJ001 , the ingredients of YJ001 placebos for spray use, aspirin, salicylic acid, or YJ001-like drugs (such as 5-aminosalicylic acid, sulfasalazine, and salicylate esters)
  • Subjects who participated in the YJ001 clinical study and received the product before
  • Subjects had widespread systemic pain that could affect the evaluation of pain at the administration site, as judged by the investigator; or the pain in the hand or more proximal area is more severe than in the foot
  • Subjects with severe peripheral vascular disease (such as intermittent claudication) who were deemed by the investigator to be unsuitable for participation in the study at the time of screening
  • Subjects have pain caused by non-diabetic peripheral neuropathy, such as active osteoarthritis, stage II or higher peripheral arterial disease, lumbar disc herniation, vitamin B deficiency, alcoholism, herpes neuralgia, vasculitis, and the somatoform pain caused by psychological disorders such as severe depression and anxiety, which may affect the investigator's score for DPNP
  • Subjects had diseases associated with elevated inflammatory factors at the time of screening, such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and atopic dermatitis
  • Presence of a skin disease in the skin area where the drug is administered, in the investigator's judgment, may affect the score for diabetic peripheral neuropathic pain; or the skin at the administration site is redness, inflamed, damaged, or otherwise affected in a way that may interfere with drug absorption; or, in the investigator's judgment, the subject has tattoos or other skin abnormalities that may interfere with the study objectives
  • The skin condition of the administration site scored >2
  • Malignant tumors, except for non- basal cell carcinoma or squamous cell carcinoma of the skin that has been appropriately treated or surgically removed, or in situ cervical cancer
  • Amputation of any part of the body other than the fingertips or toes
  • Combined with diabetes-related foot ulcers, infections, or gangrene
  • Acute diabetic metabolic complications, such as diabetic ketoacidosis, lactic acidosis, hyperosmolar hyperglycemic syndrome, or diabetic hyperosmolar coma
  • One or more episodes of severe hypoglycemia (defined as requiring assistance from others to obtain carbohydrates, glucagon, or other rescue measures) during the 6 months prior to screening or during the run-in period
  • During the one-week run-in period, the subject's NRS pain scores was \<3 more than three times
  • Subjects who have used transcutaneous electrical nerve stimulation (TENS), acupuncture, or other therapeutic measures within two weeks prior to inclusion, or who require combined transcutaneous electrical nerve stimulation (TENS) or acupuncture treatment during the treatment period
  • Use of topical analgesics for the treatment of DPNP (such as capsaicin patches, lidocaine patches, etc.) within 2 weeks prior to inclusion
  • Abnormal liver and kidney function: (AST) or alanine aminotransferase (ALT) > 2.5 times the values, creatinine > 1.5 times the upper limit of normal values
  • Combined severe cardiovascular and cerebrovascular diseases (such as second- or third-degree cardiac conduction block, heart failure classified as (NYHA) Functional Classification III-IV, myocardial infarction, acute stroke, etc.)
  • Combined severe respiratory, blood, and hematopoietic system diseases
  • Subjects with other neurological disorders (such as cognitive impairment) that the investigator think it might affect the evaluation of diabetic peripheral neuropathic pain or self-assessment, or psychiatric patients who, in the investigator's judgment, are not suitable for participation in this trial
  • Subjects with a known or suspected history of alcohol abuse, drug abuse, or dependence within the past year
  • Pregnant or lactating women; male subjects (including their female partner) and female subjects of who plan to become pregnant or cannot guarantee the use of one or more methods (common contraceptive methods include tubal ligation intrauterine devices, birth control pills, condoms, etc.) from the start of screening until three months after the end of the trial
  • Screen subjects who have participated in other clinical trials within the past 3 months
  • Other situations where the investigator considers it inappropriate to participate in this trial
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
196 participants (actual)

Study arms

  • Placebo comparator
    YJ001 spray simulator

    Drug: YJ001 spray simulator

  • Experimental
    YJ001 Spray 240 mg/day

    Drug: YJ001 Spray 240 mg/day

  • Experimental
    YJ001 Spray 480 mg/day

    Drug: YJ001 Spray 480 mg/day

  • Experimental
    YJ001 Spray 960 mg/day

    Drug: YJ001 Spray 960 mg/day

Interventions

  • DrugYJ001 spray simulator

    YJ001 spray 0mg/ml,apply spray to both feet 0mg each time,twice daily, with six sprays per foot.

  • DrugYJ001 Spray 240 mg/day

    YJ001 spray 50mg/ml,apply spray to both feet 120mg each time,twice daily, with six sprays per foot.

  • DrugYJ001 Spray 480 mg/day

    YJ001 spray 100mg/ml,apply spray to both feet 240mg each time,twice daily, with six sprays per foot.

  • DrugYJ001 Spray 960 mg/day

    YJ001 spray 200mg/ml,apply spray to both feet 480mg each time,twice daily, with six sprays per foot

06

What researchers measure

Primary outcomes

  1. Change from baseline in weekly average Numeric Rating Scale (NRS) pain score at Week 12 after treatment.

    Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity

    Time frame: baseline and week 12

Secondary outcomes

  1. Change from baseline in weekly average NRS pain scores during Week 1-11 after treatment and the follow-up period.

    Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity.

    Time frame: baseline and weekly during Weeks 1-11

  2. Change from baseline in weekly average NRS pain scores measured 6 hours after morning dosing during Weeks 1-12 after treatment.

    Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity.

    Time frame: baseline and 6 hours after morning dosing during Weeks 1-12

  3. Change from baseline in weekly average NRS pain scores before morning dosing during Week 1-12 after treatment.

    Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity.

    Time frame: baseline,before morning dosing during Week 1-12

  4. Change from baseline in weekly average NRS pain scores before evening dosing during Week 1-12 after treatment.

    Numeric Rating Scale (NRS). This scale ranges from 0 to 10, with 0 representing no pain and 10 representing the worst imaginable pain. Higher scores indicate worse pain severity.

    Time frame: baseline,before evening dosing during Week 1-12

  5. Weekly responder rates (≥30 % and ≥50 % reduction) during Week 1-12 after treatment.

    Responder is defined as ≥30% or ≥50% reduction in weekly average Numeric Rating Scale (NRS) pain score from baseline. NRS: 0-10, 0=no pain,10=worst imaginable pain, higher scores mean worse pain.

    Time frame: Weekly during Week 1-12

  6. Change from baseline in weekly average sleep interference scores during Week 1-12 after treatment and the follow-up period.

    Weekly average sleep disturbance score. The scale ranges from 0 to 10. Higher scores indicate worse sleep disturbance.

    Time frame: baseline,Week 1, 2, 4, 8, 12

  7. Change from baseline in Visual Analogue Scale (VAS) pain scores derived from the Short-form McGill Pain Questionnaire(SF-MPQ) at Week 1, 2, 4, 8, 12 after treatment and the follow-up period.

    Short-Form McGill Pain Questionnaire Verbal Analogue Scale (SF-MPQ-VAS). The scale ranges from 0 to 10. Higher scores indicate worse pain.

    Time frame: baseline,Week 1, 2, 4, 8, 12

  8. Change from baseline in Hospital Anxiety and Depression Scale (HADS) scores at Week 1, 2, 4, 8, 12 after treatment and the follow-up period.

    Hospital Anxiety and Depression Scale (HADS). Total score ranges from 0 to 42. Higher scores indicate greater anxiety and depression symptoms.

    Time frame: baseline,Week 1, 2, 4, 8, 12

  9. Patient's Global Impression of Change (PGIC) at Week 12 after treatment.

    Patient Global Impression of Change (PGIC). The scale ranges from 1 to 7. Lower scores indicate better improvement in pain.

    Time frame: Week 12

  10. Clinician's Global Impression of Change (CGIC) at Week 12 after treatment.

    Clinician's Global Impression of Change (CGIC) is a 7-point clinician-rated scale. Scores range from 1 to 7: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. Lower scores indicate better clinical improvement.

    Time frame: Week 12

  11. Change from baseline in 36-Item Short-Form Health Survey (SF-36) scores at Week 12 after treatment.

    Short Form-36 (SF-36) quality of life scale. Each domain score ranges from 0 to 100. Higher scores indicate better quality of life.

    Time frame: baseline and Week 12

  12. Change from baseline in superficial peroneal and sural nerve conduction velocity and action potential amplitude at Week 12 after treatment.

    Nerve conduction velocity and compound nerve action potential amplitude of superficial peroneal nerve and sural nerve will be measured by nerve conduction studies. The change from baseline in these electrophysiological parameters will be assessed at Week 12 after treatment. Higher nerve conduction velocity and higher amplitude indicate better nerve function.

    Time frame: baseline,Week 12

  13. Change from baseline in serum tumour necrosis factor-α (TNF-α) level at Week 12 after treatment.

    Serum tumour necrosis factor-α (TNF-α) concentration will be measured in blood samples. The change from baseline in serum TNF-α level will be evaluated at Week 12 after treatment. Lower TNF-α levels indicate reduced inflammatory status (better outcome).

    Time frame: baseline,Week 12

  14. The self-assessed time for significant pain relief by subjects after treatment (defined as pain NRS score before morning or evening dosing reduction ≥30 % from baseline).

    This endpoint measures the self-assessed time to achieve significant pain relief by subjects. Significant pain relief is defined as a ≥30% reduction from baseline in the pre-morning or pre-evening dosing Numeric Rating Scale (NRS) pain score. The NRS ranges from 0 to 10, where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate worse pain severity. The time to reach this pain relief threshold will be recorded throughout the trial.

    Time frame: before morning or evening dosing throughout the entire clinical trial period

  15. Changes in NRS pain scores before morning dosing, 1, 3, 6, 9 hours after morning dosing, and before evening dosing within 3 days after significant relief of self-reported pain by the subjects

    This endpoint evaluates changes in subject-reported Numeric Rating Scale (NRS) pain scores. Assessments are collected at pre-morning dosing, 1, 3, 6, 9 hours after morning dosing, and pre-evening dosing within 3 days after subjects report significant pain relief. The NRS ranges from 0 to 10, where 0 = no pain and 10 = worst imaginable pain. Higher scores indicate worse pain severity.

    Time frame: before morning dosing, 1, 3, 6, 9 hours after morning dosing, and before evening dosing within 3 days after significant relief of self-reported pain by the subjects

  16. Number of participants with clinically significant abnormal laboratory values

    Assessment of clinically significant abnormal laboratory values from hematology, serum biochemistry, coagulation and urinalysis tests. Laboratory panel includes hematology (RBC, Hb, WBC, NEU, PLT, NEU%, LYM%), serum biochemistry (AST, ALT, TBIL, GGT, ALP, DBIL, ALB, Scr, eGFR, HbA1c, FPG), coagulation (APTT, PT, TT, FIB, INR), urinalysis (PRO, GLU, LEU, UERY, urine pH).

    Time frame: Pre-import period,baseline,Week 4, 8, 12

  17. Number of participants with clinically significant abnormal 12/18-lead ECG findings

    Assessment of clinically significant abnormal electrocardiogram (ECG) parameters from 12-lead or 18-lead ECG recordings, including heart rate, PR interval, QRS duration, QT interval, QTc interval, and morphological abnormalities.

    Time frame: Pre-import period,baseline,Week 4, 8, 12

  18. Number of participants with respiratory tract irritation related to spray administration

    Incidence of respiratory tract irritation adverse events occurring during spray administration, assessed via clinical inquiry and physical examination at each study visit.

    Time frame: Week 1,2,4, 8, 12

  19. Any adverse events observed or reported throughout the study period will be documented promptly

    Time frame: Pre-import period,baseline,Week 1,2, 4, 8, 12

  20. Change from baseline in serum interleukin (IL-6) level at Week 12 after treatment.

    Time frame: baseline ,Week 12

  21. Change from baseline in serum interleukin IL-1β level at Week 12 after treatment.

    Time frame: baseline,week 12

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, Haidian District 100089, China
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Dec 2024, 11 months.

Of 34 industry-sponsored phase 2 interventional studies under Neuralgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's 11 months is below that.

Counting every sponsor, half of 58 studies reached it within 22 months; a quarter within 11 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Oct 5, 2026
StartActual
Jan 18, 2024
Primary completionActual
Dec 27, 2024
CompletionActual
Jan 3, 2025
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange from baseline in weekly average Numeric Rating Scale (NRS) pain score at Week 12 after treatment.: how it is measured was reworded
Oct 15, 2026
Secondary outcomes
15 description edited
What changed in the outcomes
  • DescriptionChange from baseline in 36-Item Short-Form Health Survey (SF-36) scores at Week 12 after treatment.: how it is measured was reworded
  • DescriptionChange from baseline in Hospital Anxiety and Depression Scale (HADS) scores at Week 1, 2, 4, 8, 12 after treatment and the follow-up period.: how it is measured was reworded
  • DescriptionChange from baseline in Visual Analogue Scale (VAS) pain scores derived from the Short-form McGill Pain Questionnaire(SF-MPQ) at Week 1, 2, 4, 8, 12 after treatment and the follow-up period.: how it is measured was reworded
  • DescriptionChange from baseline in serum tumour necrosis factor-α (TNF-α) level at Week 12 after treatment.: how it is measured was reworded
  • DescriptionChange from baseline in superficial peroneal and sural nerve conduction velocity and action potential amplitude at Week 12 after treatment.: how it is measured was reworded
  • DescriptionChange from baseline in weekly average NRS pain scores before evening dosing during Week 1-12 after treatment.: how it is measured was reworded
  • DescriptionChange from baseline in weekly average NRS pain scores before morning dosing during Week 1-12 after treatment.: how it is measured was reworded
  • DescriptionChange from baseline in weekly average NRS pain scores during Week 1-11 after treatment and the follow-up period.: how it is measured was reworded
  • DescriptionChange from baseline in weekly average NRS pain scores measured 6 hours after morning dosing during Weeks 1-12 after treatment.: how it is measured was reworded
  • DescriptionChange from baseline in weekly average sleep interference scores during Week 1-12 after treatment and the follow-up period.: how it is measured was reworded
  • DescriptionChanges in NRS pain scores before morning dosing, 1, 3, 6, 9 hours after morning dosing, and before evening dosing within 3 days after significant relief of self-reported pain by the subjects: how it is measured was reworded
  • DescriptionClinician's Global Impression of Change (CGIC) at Week 12 after treatment.: how it is measured was reworded
  • DescriptionPatient's Global Impression of Change (PGIC) at Week 12 after treatment.: how it is measured was reworded
  • DescriptionThe self-assessed time for significant pain relief by subjects after treatment (defined as pain NRS score before morning or evening dosing reduction ≥30 % from baseline).: how it is measured was reworded
  • DescriptionWeekly responder rates (≥30 % and ≥50 % reduction) during Week 1-12 after treatment.: how it is measured was reworded
Oct 15, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 15, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange from baseline in weekly average Numeric Rating Scale (NRS) pain score at Week 12 after treatment.: how it is measured was reworded
    Secondary outcomes 15 description edited
    What changed in the outcomes
    • DescriptionChange from baseline in 36-Item Short-Form Health Survey (SF-36) scores at Week 12 after treatment.: how it is measured was reworded
    • DescriptionChange from baseline in Hospital Anxiety and Depression Scale (HADS) scores at Week 1, 2, 4, 8, 12 after treatment and the follow-up period.: how it is measured was reworded
    • DescriptionChange from baseline in Visual Analogue Scale (VAS) pain scores derived from the Short-form McGill Pain Questionnaire(SF-MPQ) at Week 1, 2, 4, 8, 12 after treatment and the follow-up period.: how it is measured was reworded
    • DescriptionChange from baseline in serum tumour necrosis factor-α (TNF-α) level at Week 12 after treatment.: how it is measured was reworded
    • DescriptionChange from baseline in superficial peroneal and sural nerve conduction velocity and action potential amplitude at Week 12 after treatment.: how it is measured was reworded
    • DescriptionChange from baseline in weekly average NRS pain scores before evening dosing during Week 1-12 after treatment.: how it is measured was reworded
    • DescriptionChange from baseline in weekly average NRS pain scores before morning dosing during Week 1-12 after treatment.: how it is measured was reworded
    • DescriptionChange from baseline in weekly average NRS pain scores during Week 1-11 after treatment and the follow-up period.: how it is measured was reworded
    • DescriptionChange from baseline in weekly average NRS pain scores measured 6 hours after morning dosing during Weeks 1-12 after treatment.: how it is measured was reworded
    • DescriptionChange from baseline in weekly average sleep interference scores during Week 1-12 after treatment and the follow-up period.: how it is measured was reworded
    • DescriptionChanges in NRS pain scores before morning dosing, 1, 3, 6, 9 hours after morning dosing, and before evening dosing within 3 days after significant relief of self-reported pain by the subjects: how it is measured was reworded
    • DescriptionClinician's Global Impression of Change (CGIC) at Week 12 after treatment.: how it is measured was reworded
    • DescriptionPatient's Global Impression of Change (PGIC) at Week 12 after treatment.: how it is measured was reworded
    • DescriptionThe self-assessed time for significant pain relief by subjects after treatment (defined as pain NRS score before morning or evening dosing reduction ≥30 % from baseline).: how it is measured was reworded
    • DescriptionWeekly responder rates (≥30 % and ≥50 % reduction) during Week 1-12 after treatment.: how it is measured was reworded
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07858344
Lead sponsor
Zhejiang Yuejia Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Jan 18, 2024
Primary completion
Dec 27, 2024
Completion
Jan 3, 2025
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion